FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVA
-------------

Ì	OMB Number:	3235-0287
	Estimated average burden	
	hours per response:	0.5

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	of Reporting Person*		2. Issuer Name and Ticker or Trading Symbol BioRestorative Therapies, Inc. [BRTX]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Kukekov Nick	<u>.01ay v.</u>			X	Director	10% Owner			
	(First) RATIVE THERAPIE IVE, SUITE ONE	(Middle) S, INC.	3. Date of Earliest Transaction (Month/Day/Year) 11/03/2022	_	Officer (give title below)	Other (specify below)			
(Street)  MELVILLE NY  (City) (State)		11747 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv	idual or Joint/Group Filing Form filed by One Repo Form filed by More than	rting Person			

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

or occurry (moure)		2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.	or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	3 and 4)		(Instr. 4)

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Ir 8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Reported Transaction(s) (Instr. 4)		
Stock Option	\$13.5	11/03/2022		D			25,236	(1)	11/04/2031	Common Stock	25,236	\$0 <sup>(2)</sup>	0	D	
Stock Option	\$5.08	11/03/2022		A		25,236		(1)	11/04/2031	Common Stock	25,236	\$0 <sup>(2)</sup>	25,236	D	

# Explanation of Responses:

- 1. The option vests and becomes exercisable to the extent of 12,618 shares on November 4, 2021 with the remaining 12,618 shares vesting quarterly in eight nearly equal installments beginning November 4, 2022 and continuing every three months thereafter until fully vested.
- 2. The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option with a reduced exercise price.

/s/ Nickolay Kukekov

11/03/2022

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.